Chinese API maker investing $145M in plant to make biologics by Eric Palmer Wednesday, December 5, 2018 A Chinese maker of heparin and APIs for oncology and other drugs is investing nearly $150 million as it targets innovative drugs for China.
Changzhou Fangyuan plans trials on hard-to-make antibiotic by EJ Lane Wednesday, July 13, 2016 Changzhou Fangyuan Pharma is ready for clinical trials in China to test its nearly decade-long work on a tricky-to-make semisynthetic, methicillin-resistant and gram-negative infection-fighting antibiotic.
